Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma

Published:2017-04-20 Issue:6 Volume:13 Page:4917-4924
ISSN:1792-1074
Container-title:Oncology Letters
language:en
Short-container-title:

Author:

Sarabi Matthieu,Mais Laetitia,Oussaid Nadia,Desseigne Françoise,Guibert Pierre,De La Fouchardiere Christelle

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Gemcitabine Plus Nab-paclitaxel in Second-line Treatment of Metastatic Pancreatic Cancer: a Multicenter Retrospective Study in Turkey;2024-09-10

2. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment;Cancer Medicine;2024-06

3. French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients;Therapeutic Advances in Medical Oncology;2024-01

4. Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer;Health Data Science;2024-01

5. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation;Biomedical Journal;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP